Daxor Corporation (DXR)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

8.16

0.00%

After-hours Dec 13, 2024, 02:12 PM EST

Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.

The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Daxor Corporation

Country	United States
IPO Date	Jul 25, 1983
Industry	Medical - Instruments & Supplies
Sector	Healthcare
Employees	37
CEO	Michael Richard Feldschuh

Contact Details

Address: 109 Meco Lane Oak Ridge, Tennessee United States
Website	https://www.daxor.com

Stock Details

Ticker Symbol	DXR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0000027367
CUSIP Number	239467103
ISIN Number	US2394671034
Employer ID	13-2682108
SIC Code

Key Executives

Name	Position
Michael Richard Feldschuh	Chairman, President & Chief Executive Officer
Robert J. Michel CPA, CPA, M.B.A.	Chief Financial Officer, Chief Compliance Officer & Corporate Secretary
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H.	Chief Medical Officer
Guido Manzo	Vice President of Sales
Jean Oertel	Senior Vice President Commercialization & Customer Experience
Jonathan Adam Feldschuh	Chief Scientific Officer & Director
Kathryn A. Kornafel	Senior Vice President of Marketing & Commercial Development
Linda Cooper	Vice President of Development & Operations

Latest SEC Filings

Date	Type	Title
Dec 10, 2024	4	Filing
Dec 10, 2024	4	Filing
Dec 10, 2024	4	Filing
Nov 21, 2024	NPORT-P	Filing
Sep 10, 2024	N-PX	Filing
Aug 29, 2024	NPORT-P	Filing
Aug 29, 2024	N-CSRS	Filing
Aug 23, 2024	40-17G	Filing
Aug 16, 2024	N-2	Filing
Jul 18, 2024	8-K	Current Report

View All SEC Filings